

THE  
**3<sup>RD</sup>**  
SOHO  
ISRAEL  
MEETING

THE  
**9<sup>TH</sup>**  
INTERNATIONAL  
DAVIDOFF  
CONFERENCE

soho  ISRAEL  
SOCIETY OF HEMATOLOGIC ONCOLOGY

# SPEAKERS' BOOK

מרכז דוידוף  
*Davidoff Center*



ISRAEL SOCIETY OF HEMATOLOGY  
AND TRANSFUSION MEDICINE



RABIN MEDICAL CENTER  
BEILINSON • HASHARON



אוניברסיטת תל אביב  
TEL AVIV UNIVERSITY

KALEIDOSCOPE  
Conferences | Events | Exhibitions

03-5445015 | ארגון  
kldltd.com | והפקה

## Meeting Chairs' Greetings

For the past 8 years, the annual International Davidoff Conference has been a tradition.

SOHO – The Society of Hematologic Oncology, established in 2012 by the MD Anderson Group, has grown to over 9,000 members from 120 countries, aiming to expedite worldwide research and education in hematologic malignancies.

In 2023, Prof. Hagop Kantarjian and Prof. Pia Raanani launched the yearly SOHO – Israel meeting's program, merged with the traditional Davidoff conference.

In the past 2 years, the meeting gathered 530 participants, both physically and virtually.

This year's meeting titled the **"3rd SOHO – Israel Meeting and the 9th International Davidoff Conference – State of the Art and Next Questions..."**, will be held on **May 15th–16th, 2025** in Tel Aviv, Israel.

The 2 days with 34 educational lectures will focus on new advances and clinical applications in hematologic malignancies, with speakers representing international experts in the field.

Alongside the conference, there will be an innovative exhibition of pharmaceutical and medical equipment companies.

As a hybrid event, it offers in-person attendance for Israeli participants and virtual options for international attendees.

We invite you to join us for this exciting meeting and encourage you to become a SOHO member for free at [sohoonline.org](https://sohoonline.org) !

***Prof. Pia Raanani and Prof. Hagop Kantarjian***

Meeting Chairs

## Scientific Program

### STATE OF THE ART AND NEXT QUESTIONS

# Thursday, May 15th 2025

**ANU – Museum of the Jewish People, Tel Aviv**

**08:00–09:00**

**Registration, Gathering, & Exhibition**

**09:00–09:30**

#### **Opening Remarks**

**Hagop Kantarjian, MD**, Chair of the Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA

**Eytan Wirthem, MD, MHA, CEO** – Beilinson & Hasharon Hospitals – Rabin Medical Center, Clalit Health Services, Israel

**Karen Avraham, PhD**, Dean of the Faculty of Medical & Health Sciences, Tel-Aviv University, Israel

**Galia Stemer, MD**, in the name of the Israel Society of Hematology and Blood Transfusions

**Gal Markel, MD**, Head, Davidoff Cancer Center, Rabin Medical Center, Israel

**Mr. Paul Davidoff**, on behalf of the Davidoff Family

**Pia Raanani, MD**, Head, Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Israel

**09:30–10:50**

**Session 1 – Chronic Lymphocytic Leukemia**

**Chairpersons –**

**Liron Hofstetter, MD | Yair Herishanu, MD**

09:30–09:50	Prognostication and Management of Early Stage CLL <b>Barbara Eichhorst, MD, University Hospital of Cologne, Germany</b>
09:50–10:10	BTK Inhibitors: Long-Term Responses and Differential Responses in IGHV Subsets <b>Jan Burger, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b>
09:10–10:30	Chronic Lymphocytic Leukemia: Evolution of Frontline Treatment <b>Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b>
10:30–10:50	Management of Relapsed/Refractory CLL and New Treatments on the Horizon <b>William (Bill) Wierda, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b>

**10:50–11:10**

**Coffee Break & Exhibition**

**11:10–12:20**

## **Session 2 – Plasma Cell Dyscrasias**

**Chairpersons –**

**Iuliana Vaxman, MD | Moshe Gatt, MD**

- |             |   |
|-------------|---|
| 11:10–11:30 | High-Risk Smoldering Multiple Myeloma: Is There a Simple Solution?<br><b>Angela Dispenzieri, MD, Mayo Clinic Rochester Minnesota, USA</b>       |
| 11:30–11:50 | Should Patients Still Undergo BMT for Myeloma?<br><b>Morie Gertz, MD, Mayo Clinic Rochester Minnesota, USA</b>                                  |
| 11:50–12:10 | Real World Updates for RRMM T Cell-Redirecting Therapies<br><b>Krina Patel, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b> |
| 12:10–12:20 | <b>Panel Discussion</b>   |

**12:20–13:05**

**Lunch & Exhibition**

**13:05–14:15**

## **Session 3 – Acute Myeloid Leukemia**

**Chairpersons: Ofir Wolach, MD | Irina Amitai, MD**

- |             |  |
|-------------|--|
| 13:05–13:25 | Mutant NPM1 AML: The Poster Child for MRD Use<br><b>Richard Stone, MD, Dana Farber Cancer Institute, Boston, USA</b>                   |
| 13:25–13:45 | Emerging Novel Therapeutics in AML<br><b>Gail Roboz, MD, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, USA</b> |
| 13:45–14:05 | Treating Acute Myeloid Leukemia in 2025<br><b>Courtney DiNardo, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b>    |
| 14:05–14:15 | <b>Panel Discussion</b>  |

**14:15–14:30**

**Coffee Break & Exhibition**

**14:30–16:30**

## **Session 4 – Lymphoma**

**Chairpersons: Nadav Sarid, MD | Uri Abadi, MD**

- |             |   |
|-------------|---|
| 14:30–14:50 | Next Steps in Hodgkin Lymphoma<br><b>Alison Moskowitz, MD</b> , <i>Memorial Sloan Kettering Cancer Center, NY, USA</i>  |
| 14:50–15:10 | Incorporating Biology into Upfront Therapy for Systemic T-Cell Lymphomas<br><b>Steve Horwitz, MD</b> , <i>Memorial Sloan Kettering Cancer Center, NY, USA</i>                         |
| 15:10–15:30 | Updates in PTCL Treatment<br><b>Swaminathan Padmanabhan Iyer, MD</b> , <i>University of Texas MD Anderson Cancer Center, Houston, USA</i>   |
| 15:30–15:50 | Navigating the Diffuse Large B-cell Lymphoma Landscape in 2025<br><b>Gilles Salles, MD</b> , <i>Memorial Sloan Kettering Cancer Center NY, USA</i>                                    |
| 15:50–16:10 | Updates in Marginal Zone Lymphoma<br><b>Izidore Lossos, MD</b> , <i>Division of Hematology, Department of Medicine, University of Miami and Sylvester Comprehensive Cancer Center</i> |
| 16:10–16:30 | Mantle Cell Lymphoma: Current Standards and Future Studies<br><b>Martin Dreyling, MD, PhD</b> , <i>Ludwig Maximilian, University of Munich, Germany</i>                               |

**16:30–17:20**

**Session 5 – Quality of Life in Hematological Disorders**

**Chairpersons: Alon Rozental, MD | Ariel Aviv, MD**

16:30–16:50

Quality of Life in AML and MDS

**Fabio Efficace, MD**, *Fondazione GIMEMA – Franco Mandelli Onlus, Roma, Italy*

16:50–17:10

Quality of Life in CML

**Philipp Le Coutre, MD**, *Charité – Universitätsmedizin Berlin, Germany*

17:10–17:20

**Panel Discussion**

**17:20–17:30**

**Closing Remarks**

**Friday, May 16th 2025**

**Port Tower Hotel, Tel Aviv**

**08:00–08:30** *Gathering*

**08:30–10:30**

**Session 6 – Myeloproliferative &  
Myelodysplastic Disorders**

**Chairpersons:**

**Adi Shacham – Abulafia, MD | Galia Stemer, MD**

08:30–08:50	Myeloproliferative Neoplasms <b>Lucia Masarova, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b>
08:50–09:10	Management of Systemic Mastocytosis in 2025 <b>Jason Gotlib, MD, Hematology, Stanford Cancer Center Palo Alto, Palo Alto California</b>
09:10–09:30	New Paradigms in MDS <b>Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b>
09:30–09:50	How Can We Improve Outcomes in Patients with Higher Risk MDS <b>David A Sallman, MD, Moffitt Cancer Center Tampa, Florida, USA</b>
09:50–10:10	How I Treat CMML <b>Eric Padron, MD, Moffitt Cancer Center, Tampa, Florida, USA</b>
10:10–10:30	How to Choose the Best Therapeutic Approach in LR MDS <b>Valeria Santini, MD, University of Florence, Florence, Italy</b>



**10:30–12:10**

## **Session 7 – Chronic Myeloid Leukemia**

**Chairpersons:**

**Pia Raanani, MD | Noam Benyamini, MD**

- |             |  |
|-------------|--|
| 10:30–10:50 | Challenges in the Upfront Treatment of CML<br><b>Delphine Rea, MD, Hopital Saint-Louis, Paris, France</b>  |
| 10:50–11:10 | Mechanisms of Resistance to Asciminib<br><b>Simona Soverini, PhD, Alma Mater Studiorum Universita di Bologna, Italy</b>                              |
| 11:10–11:30 | Questions and Answers on CML Treatment that Can Derive from the Analysis of Real-Life Data<br><b>Giuseppe Saglio, MD, University of Turin, Italy</b> |
| 11:30–11:50 | How I Manage CML at MD Anderson in 2025<br><b>Hagop Kantarjian, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b>                  |
| 11:50–12:10 | <b>Panel Discussion</b>  |

**12:10–12:30**

**Coffee Break**

**12:30–13:30**

## **Session 8 – Cellular Therapy**

**Chairpersons: Batia Avni, MD | Avichai Shimoni, MD**

- |             |  |
|-------------|--|
| 12:30–12:50 | Current State and Future Directions of Cell Therapy for B-cell Lymphomas<br><b>Nirav N Shah, MD, Medical College of Wisconsin, Milwaukee, Wisconsin, USA</b> |
| 12:50–13:10 | Role of Allogeneic Transplantation in Adult ALL in 2025<br><b>Issa F Khouri, MD, University of Texas MD Anderson Cancer Center, Houston, USA</b>             |
| 13:10–13:30 | Cellular Therapy for AML – The Next Questions<br><b>Koen van Besien, MD, PhD, UH Seidman Cancer Center, Cleveland, Ohio, USA</b>                             |

**13:30–14:55**

**Session 9 – Acute Lymphoblastic Leukemia**

**Chairpersons: Anat Gafter-Gvili, MD | Yakir Moshe, MD**


- |             |   |
|-------------|---|
| 13:30–13:50 | ALL Research and Therapy at MD Anderson in 2025<br><b>Hagop Kantarjian, MD</b> , <i>University of Texas MD Anderson Cancer Center, Houston, USA</i>   |
| 13:50–14:10 | How Blinatumomab-Based Treatment is Changing the Management and Outcome of B-ALL<br><b>Robin Foà, MD</b> , <i>Department of Translational and Precision Medicine, Sapienza, University of Rome, Rome, Italy</i> |
| 14:10–14:30 | Frontline Treatment of Ph+ ALL and the Emerging Role of Chemotherapy-Free Regimens<br><b>Nicholas J Short, MD</b> , <i>University of Texas MD Anderson Cancer Center, Houston, USA</i>                          |
| 14:30–14:55 | <b>Panel Discussion</b>   |
| 14:55–15:00 | <b>Closing Remarks</b>  |

# INVITED SPEAKERS

## Hagop Kantarjian, MD

---

*University of Texas MD Anderson Cancer Center, Houston, USA*



Dr Hagop Kantarjian is Chair of the Leukemia Department at MD Anderson Cancer Center in Houston, Texas. He is a fellow in health care policies at the Baker Institute at Rice University.

His research focuses on translational-clinical developmental therapeutics in leukemia.

Over the past 4 decades, he has made numerous contributions that improved patient prognosis and survival across the leukemia entities, with over 2,400 peer reviewed publications.

In addition to his 40+ year career as a leukemia researcher, he has been involved in health care policies, and published extensively on issues related to the Affordable Care Act (ObamaCare), health care as a human right, cancer drug prices, 340B, HPV vaccines, and others.

## Barbara Eichhorst, MD

---

*University Hospital of Cologne, Germany*

Barbara Eichhorst graduated at the Medical school of the University of Munich and wrote her doctoral thesis in the field of hematology evaluating signalling transduction pathways in Hodgkin cells.



Dr Eichhorst finished her internship at the department III for internal medicine of the University of Munich and specialized in internal medicine. Since February 2005 she works at the Department I for Internal Medicine and Center for Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf at the University hospital of Cologne and finished her specialisation in hematology and internal oncology. She is assistant professor and consultant since December 2012 and adjunct professor of the University of Cologne since July 2019.

Her main focus of interest is chronic lymphocytic leukemia (CLL). As leading group member of the German CLL Study Group (GCLLSG) she was and is principal investigator in several phase II and III trials evaluating treatment optimization in CLL. Since 2005 she is secretary of the GCLLSG (head Prof. Dr. Michael Hallek), deputy chair since 2022 and chair of the GCLLSG since 2024.

Dr. Eichhorst published many papers in the field of prognostication and treatment of CLL as well as Richter transformation including national and international guidelines.


She is also a member of several national and international organizations including the European Haematology association and American Society of Hematology and was elected as member of International Workshop of CLL (iwCLL) in 2019.

## Jan Burger, MD

---

*University of Texas MD Anderson Cancer Center, Houston, USA*

Jan A. Burger, M.D., Ph.D. is a Professor of Medicine at the MD Anderson Cancer Center in Houston, USA.



Dr. Burger received his M.D./Ph.D. degree at Albert-Ludwigs-University in Freiburg, Germany, with subsequent clinical training and board certification in Internal Medicine and Hematology/Oncology at Freiburg University Hospital, before moving to MD Anderson in 2005. In 2006, Dr. Burger received the “Venia legendi” (Habilitation) for Internal Medicine at Albert-Ludwigs-University in Freiburg. Moreover, from 1996 to 1999, Dr. Burger received postdoctoral research training in Hematology and Immunology at the University of California, San Diego.

As a clinical and laboratory investigator, Dr. Burger focuses on developing new therapeutic approaches for targeting the microenvironment in chronic lymphocytic leukemia (CLL), other B cell malignancies, and acute leukemias. Laboratory research by Dr. Burger’s group characterized B cell receptor (BCR)-associated kinases, such as BTK and PI3 kinases, as therapeutic targets.

Dr. Burger serves as a principal investigator on clinical trials which explore these targets in CLL, and has been leading key trials that supported the approval of the BTK inhibitor ibrutinib (Resonate 2: ibrutinib for CLL frontline therapy).

For his innovative research, Dr. Burger received several awards, among them, the Arthur Pappenheim Award by the DGHO, a Kimmel Scholar Award, ASCO Young Investigator and Career Development awards, the Leukemia and Lymphoma Society Scholar award, and the MD Anderson Faculty Scholar Award.

Dr. Burger is a regular speaker at EHA and ASH, and has published in the leading Journals in his field.

## Nitin Jain, MD

---

*University of Texas MD Anderson Cancer Center, Houston, USA*



Nitin Jain, M.D., is a Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas, USA. He earned his medical degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2002. He completed Internal Medicine residency at the Medical College of Wisconsin, Milwaukee. He then completed clinical fellowship in Leukemia at MDACC followed by a Leukemia research fellowship at Memorial Sloan-Kettering Cancer Center. He then pursued fellowship in Hematology/Oncology at The University of Chicago. He joined as a faculty in the Department of Leukemia at MDACC in July 2012.

Dr. Jain treats patients with acute and chronic leukemias with focus of patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). Dr. Jain research interests focus on new drug development for patients with leukemia, especially CLL and ALL. Since 2021, he has also served as Director, Leukemia CAR-T Program within the Department of Leukemia, MDACC.

Dr. Jain is Principal Investigator of several investigator-initiated phase I-II clinical trials, including combination targeted therapies (ibrutinib and venetoclax) in CLL, checkpoint inhibitor in Richter transformation, JAK2 inhibitor ruxolitinib in Ph-like ALL, novel CD22 antibody drug conjugate in B-ALL, venetoclax + chemotherapy in B- and T-ALL, ponatinib in T-ALL, and off-the-self allogeneic CARTs in B-ALL. The trial combining ibrutinib and venetoclax was published in New England Journal of Medicine in 2019. He has published papers in prominent journals including NEJM, Lancet, JAMA Oncology, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Leukemia & Lymphoma, and others. He has won many awards during his career including Sardari Lal Kalra Gold Medal in Microbiology from AIIMS and Merit Award from the American Society of Clinical Oncology (ASCO). He secured first rank at the national level in India in the medical school (AIIMS) entrance examination. He received High-Impact Clinical Research Support Award from MD Anderson


Cancer Center in the year 2014 and 2016. He has served as faculty on American Society of Hematology CRTI workshop from 2017–2019. He is recipient of Sabin Family Foundation Award in 2018. In 2020, he received MD Anderson Faculty Scholar award. In 2021, he was appointed Director of the CAR-T program for the Leukemia Department, MDACC. In 2022, he received Leukemia and Lymphoma Society (LLS) Career Development Program (CDP) Award as well as LLS Translational Research Program (TRP) award.



## **William (Bill) Wierda, MD**

---

*University of Texas MD Anderson Cancer Center, Houston, USA*



William G. Wierda, MD, PhD, is Professor of Medicine, Deputy Chair and Center Medical Director for the Department of Leukemia, and Executive Medical Director inpatient medical services at The University of Texas MD Anderson Cancer Center.

Dr. Wierda received his Doctor of Philosophy in microbiology and immunology and his medical degree from the University of Health Sciences/The Chicago Medical School. He subsequently completed an internship and residency in internal medicine at Duke University Medical Center, followed by a fellowship in hematology and medical oncology at the University of California, San Diego.

Dr. Wierda has been faculty at UT MDACC since 2001. Dr. Wierda's research focuses on studying immunology and immune function in patients with chronic lymphocytic and developing combined targeted therapies and immune-based therapeutic strategies for patients with hematologic malignancies, particularly CLL. He has served as principal investigator or co-investigator for numerous clinical trials, lectured nationally and internationally, and published extensively on clinical and translational aspects of CLL and drug and treatment development.

Dr. Wierda is an executive member of the International Workshop on CLL and member of the American College of Physicians, the American Society of Hematology, the American Society of Clinical Oncology, the American Association of Immunologists, and the European Society of Hematology.

Dr. Wierda serves as Chair of the NCCN CLL/SLL and Hairy Cell Leukemia Panel, the Value Pathways Task Force Member for the NCCN CLL/SLL/Hairy Cell Leukemia Panel. He also serves as peer reviewer for several journals and is an editorial board member for JNCCN—Journal of the National Comprehensive Cancer Network and a scientific review committee member for the NCCN Oncology Research Program.

## Angela Dispenzieri, MD

---

*Mayo Clinic Rochester Minnesota, USA*



Angela Dispenzieri, M.D., is a consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic. She has joint appointments in the Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, and the Department of Molecular Medicine. Dr. Dispenzieri holds the academic rank of Professor of Medicine and of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, and she is recognized with the distinction of a named professorship, the Serene M. and Frances C. Durling Professorship. She joined the staff of Mayo Clinic in 1998 and served as Chair of Hematology Research from 2014 to 2022. She currently chairs the Mayo Clinic Amyloid Interest Group.

Dr. Dispenzieri earned her B.S. in biology at the Massachusetts Institute of Technology and her M.D. at Albert Einstein College of Medicine. She subsequently completed a residency and a fellowship in Hematology and Oncology at Mayo Clinic.

Dr. Dispenzieri conducts research in plasma cell disorders, including multiple myeloma, amyloidosis, POEMS syndrome and other rare plasma cell disorders. Her joint appointments in Hematology and Clinical Chemistry are conducive to clinical and translational research in these fields. She also specializes in clinical trials—with a special interest in virotherapy – and stem cell transplantation. She is the Director of the Biospecimens Core of the Mayo Clinic Myeloma SPORE. Dr. Dispenzieri is frequently invited to give presentations on her research both domestically and internationally, and she has held editorial and reviewer responsibilities for several prominent publications. and she has been an author or co-author on over 600 journal articles, book chapters, and abstracts in the field of plasma cell disorders, including multiple myeloma, immunoglobulin light chain amyloidosis, POEMS syndrome, Castleman Disease, and mass spectrometry techniques.

She has had leadership roles in international amyloid and myeloma societies

including being a past treasurer and past president of the International Society of Amyloidosis and past treasurer for the International Myeloma Society. She is President of the International Kidney and Monoclonal Gammopathy Society.

In addition to her clinical and research activities, Dr. Dispenzieri is active in education and provides mentorship to many residents and fellows.

## Morie Gertz, MD

---

*Mayo Clinic Rochester Minnesota, USA*

Dr. Gertz is the Roland Seidler Jr. Professor of the Art of Medicine and Chair Emeritus of the Department of Internal Medicine, at Mayo Clinic in Rochester, Minnesota. He is a Master of the American College of Physicians.



Undergraduate degree was awarded with highest distinction from Northwestern University graduating Phi Beta Kappa. Dr. Gertz received his medical degree cum laude from Loyola Medical School in Maywood, Illinois and was elected to Alpha Omega Alpha the medical honor society. He completed a 3-year medical residency at Rush Presbyterian St. Luke's Hospital in Chicago, Illinois, and was voted Resident of the Year for 2 of those years. He completed training in hematology and oncology at Mayo. He was awarded the Mayo Distinguished Clinician Award for his contributions to patient care. He served 1 year term as president of the Mayo clinic staff officers and counselors. he has served as chair of the division of Hematology and chair of the department of Medicine at Mayo Clinic Rochester. He was the first treasurer of the International Society of Amyloidosis and International Myeloma Society. He has authored over 1000 peer reviewed publications and over 90 book chapters. He serves on the editorial boards of Amyloidosis, Acta Haematologica and Clinical Lymphoma & Myeloma.

He is coeditor of Neoplastic Diseases of the Blood. In 2019 The Department of Medicine awarded him its lifetime research achievement award. In 2024 he became chair of the Hematology Board for the American Board of Internal Medicine.

## Krina Patel, MD

---

*University of Texas MD Anderson Cancer Center, Houston, USA*



Dr Krina K. Patel is an associate professor in the Department of Lymphoma and Myeloma, Division of Cancer Medicine, and was previously in the Department of Stem Cell Transplantation, at the University of Texas MD Anderson Cancer Center (UT MDACC) in Houston Texas.

She earned her bachelor's degree at the University of Pennsylvania, medical degree from the University of Texas Southwestern Medical Center, Dallas and completed a fellowship in hematology-oncology at UT MDACC where she served as Chief fellow for 2 years and completed her Master of Science in the lab of Laurence Cooper MD PHD evaluating the combination of NY-ESO-1 T-APC vaccine with TCR in Multiple Myeloma cell line and mouse models. She currently serves as Service Line Leader for her department.

Dr Patel's research focus is on improving therapy and outcomes for patients with MM and other plasma cell dyscrasias. Her specific research interests include improving survival and quality of life for patients with MM, POEMS, and plasmablastic lymphoma, using cellular therapy such as chimeric antigen receptor T cells with or without transplant and combining immunotherapy in the induction, transplant, maintenance, and salvage settings. She has acted as principal investigator on several MM clinical trials with a focus on immunotherapies such as novel CAR T, monoclonal antibodies, cytokines, and vaccine studies. She is also currently co-PI for a translational study evaluating ctDNA and scRNAseq data for patients undergoing standard of care CAR T studies. Outside of her clinical and translational interests, Dr. Patel is dedicated to improving outcomes and access to these novel therapies for vulnerable patient populations such as minority patient groups and those with high risk disease.

Dr Patel is a member of ASH, ASCO, ASGCT, AACR, and ASTCT. Her research has been published in numerous peer-reviewed journals.

## Richard Stone, MD

---

*Dana Farber Cancer Institute, Boston, USA*

Richard Stone, MD, is the Lunder Family Chair in Leukemia and Chief of Staff at Dana-Farber Cancer Institute. He is also Director of Translational Research for the Adult Leukemia Program, at DFCI, and Professor of Medicine at Harvard Medical School. Dr. Stone is nationally recognized for translational and clinical research in blood and bone marrow malignancies including acute leukemia, myeloproliferative disorders and myelodysplastic syndrome (MDS). He has had a significant leadership role in the development of at least five recently approved agents for the treatment of acute myeloid leukemia (AML).



In addition to his work at Dana-Farber, Dr. Stone is a Vice Chair of the National Comprehensive Cancer Network (NCCN) MDS panel and is also a member of the NCCN AML panel. He previously served as the Chair of the Alliance Leukemia Committee, Chair of the Medical Advisory Board of the Aplastic Anemia and MDS International Foundation, and the Chair of the ABIM Oncology Board.

Dr. Stone has participated extensively in teaching medical students, residents, and fellows, as well as graduate medical education courses on leukemia and related disorders. He is the author of many academic papers that have been published in the New England Journal of Medicine, Blood, Leukemia as well as numerous other journals. He has also served on the editorial boards of Leukemia Research, Blood and Journal of Clinical Oncology.

## **Gail Roboz, MD**

---

*Weill Cornell Medicine, The New York Presbyterian Hospital, New York, USA*

William S. Paley Professor of Medicine  
Director, Clinical and Translational Leukemia Programs  
Weill Cornell Medicine  
The New York Presbyterian Hospital  
New York, New York, USA



Dr. Roboz is an internationally recognized expert in developmental therapeutics and novel clinical trials for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts.

Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology co-chairs the clinical committee of the European Leukemia Net (ELN) working group on measurable residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

## Courtney DiNardo, MD

---

*University of Texas MD Anderson Cancer Center, Houston, USA*



Dr. DiNardo is an academic clinician with a focus on individualized therapy and precision oncology for myeloid malignancies, including the optimal incorporation of genomics into standard risk assessments and treatment algorithms, and the clinical evaluation of targeted therapeutics for molecularly-defined patient subgroups.

Dr. DiNardo has extensive experience in designing and implementing clinical trials in AML and has served an integral role in several highly influential trials involving IDH1, IDH2 and BCL2 inhibitors, which have led to the FDA approval of three therapies in AML since 2017 (the first-in-class IDH2 inhibitor enasidenib, the IDH1 inhibitor ivosidenib, and the BCL2 inhibitor venetoclax in combination with hypomethylating agents).



## Alison Moskowitz, MD

---

*Memorial Sloan Kettering Cancer Center, NY, USA*

Dr. Alison Moskowitz is an Associate Attending within the Lymphoma service at Memorial Sloan Kettering Cancer Center. She earned her medical degree at Albert Einstein College of Medicine, completed an internship and residency in internal medicine at Columbia University Medical Center, and completed fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.



Dr. Moskowitz's research is dedicated to developing new treatment strategies for T-cell lymphoma and relapsed/refractory Hodgkin lymphoma.

Her research program in Hodgkin lymphoma focuses on developing novel treatment approaches for patients with relapsed or refractory disease and identifying factors predictive of response to therapy and overall outcomes.

The aim of this work is to ultimately develop individualized therapy for patients with Hodgkin lymphoma that optimizes cure and limits long term toxicity.

For T-cell lymphoma, she aims to develop new agents through clinical trials that incorporate strong correlative studies aimed at identifying markers of sensitivity and resistance. These studies will allow us to design personalized treatment approaches, predict optimal combination strategies, and ultimately improve prognosis by rationally designing regimens that target the diverse T-cell lymphoma entities.

## Steve Horwitz, MD

---

*Memorial Sloan Kettering Cancer Center, NY, USA*

Dr. Steven Horwitz is an Attending Physician in the Department of Medicine at Memorial Hospital for Cancer and Allied Diseases and a Member at Memorial Sloan Kettering Cancer Center in New York City. He earned his medical degree at Case Western Reserve University School of Medicine, completed an internship and residency in internal medicine at the University of Rochester/Strong Memorial Hospital, and then completed a fellowship in medical oncology at Stanford University Medical Center.



Much of his current research is dedicated to investigating targeted or immunotherapeutic approaches to try to identify better, and often less toxic treatments for individuals with T-cell lymphomas. His research also focuses on better understanding mechanisms of response and resistance to novel drugs in T-cell lymphoma to help provide individualized treatments in the future.

Dr. Horwitz participates in several national, and international committees and consortiums dedicated to the understanding and advancement of treatment for T-cell lymphoma. Since 2017 he has been the Chair of the NCCN panel on Guidelines for Treatment of T-Cell/Primary Cutaneous B-Cell Lymphomas.

## Swaminathan P. Iyer, MD

---

*University of Texas MD Anderson Cancer Center, Houston, USA*



Dr. Swaminathan Iyer, MD is a Professor of Medicine at University of Texas, MD Anderson Cancer Center Houston, TX as a Lymphoma specialist. Prof. Swami iyer is an internationally recognized expert in clinical trials for cancer with two FDA approvals, in lymphoma and leukemia. He graduated from Bangalore Medical College, Rajiv Gandhi University of Health Sciences with a Gold Medal in Pathology in 1994. His post-graduation includes training at AIIMS, Wayne State University and University of Miami and is a American Board of Internal Medicine (ABIM) Diplomate in Internal Medicine and Hematology.

In addition, he has a laboratory interest in aptamers, chimeric antigen receptor Therapies (CAR-Ts), and machine learning approaches to predict biomarkers from whole slide images. At the University of Texas MD Anderson, he leads the T cell lymphoma (TCL) program. This involves collaboration with a multidisciplinary team in several research areas, including clinical trials with novel agents and cellular therapies, epidemiology, risk factors, and new risk prediction models. The rarity of the disease requires collaborative efforts to translate treatment advances. As the largest consortium of its kind, it could remove preventable roadblocks to collect and evaluate each TCL subtype, improve sample collection for genomic testing, and enroll more patients in clinical trials. Furthermore, it will accelerate the enrollment of newer therapies, including histone deacetylase inhibitors, EZH1/2 inhibitors, Pi3K inhibitors, Syk inhibitors, immune checkpoint inhibitors, CD47 blockers, and cellular therapies for TCL.

Dr.Iyer serves as the President of the Indo American Cancer Association with the goal of giving back service and care for cancer patients in India. He is the recipient of several awards including American Society of Clinical Oncology Young Investigator Award, Outstanding Physician Volunteer for the Leukemia Lymphoma Society, Virginia and Cockrell Presidential Scholar at the Houston Methodist, Who's Who in Healthcare, America's Top Physicians, 2007-present, HealthCare Network Excellence Award 2017 and 2022. His work has been


supported by grants from American Cancer Society, Leukemia Lymphoma Society, National Institute of Health and several industry partners. He enjoys mentoring high school and college students to gear them towards the next generation of physician scientists. His twitter handle is @Bloodbytes or @DrSwami\_Iyer.

## Gilles Salles, MD

---

*Memorial Sloan Kettering Cancer Center NY, USA*

Gilles Salles, MD, PhD, was appointed Chief of the Lymphoma Service at MSK in 2020. He previously held the position of Professor of Hematology and Medicine at the University of Lyon and Head of the Department of Hematology at the Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, in Pierre-Bénite, France.



Dr. Salles obtained his medical degree and his doctoral degree in differentiation, genetics, and immunology from the Université Claude Bernard Lyon-1. He completed further training as a researcher in oncology at the Dana-Farber Cancer Institute of Harvard Medical School.

Throughout his career, Dr. Salles has been especially interested in the clinical and biological study of lymphoma. The primary focus of his work is on the description and validation of prognostic factors and clinical trials in indolent lymphomas. His team has also examined several aspects of lymphoma biology, including T-cell and B-cell lymphoma models, signaling, and genomic biology of indolent lymphomas.

Dr. Salles has been involved in the investigation and development of new therapeutic agents such as targeted therapies, new monoclonal antibodies, and other immunotherapies in the field. He has led large international studies evaluating treatment options in patients with follicular lymphoma.

A member of several international societies, including the American Society of Hematology, Dr. Salles is also the author of more than 600 publications, including articles in international peer-reviewed journals such as The New England Journal of Medicine, Blood, The Journal of Clinical Oncology, The Lancet, Haematologica, Lancet Oncology, and Leukemia and Lymphoma.

## Izidore Lossos, MD

*Division of Hematology, Department of Medicine, University of Miami and Sylvester Comprehensive Cancer Center*



Dr. Izidore S. Lossos is a Professor of Medicine, Chief of Lymphoma Section, and the Director of Lymphoma Program at Sylvester Comprehensive Cancer Center at University of Miami. He holds a Sylvester endowed chair at the cancer center. He received his medical degree from Hadassah School of Medicine, Hebrew University in Jerusalem, Israel. He completed his residency in Internal Medicine and fellowship in Hematology at Hadassah University Hospital in Jerusalem and postdoctoral fellowship with major emphasis on lymphoma at Division of Medical Oncology at Stanford University.

The focus of Dr. Lossos research is pathogenesis of lymphoma, identification of molecular prognostic markers and elucidation of their role in determination of response to therapy, development of new lymphoma therapies. His studies focus on diffuse large cell lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, primary CNS lymphoma, lymphomas of the eye and other lymphoma subtypes. He is National and International experts in Marginal Zone Lymphomas. His research involves basic research at the bench and translation of these findings to clinical trials. He participated in multiple clinical trials as a PI or co-PI. He has authored multiple reviews, commentaries and book chapters as well as more than 340 peer-reviewed articles in such journals as New England Journal of Medicine, Blood, Proceedings of the National Academy of Sciences USA, Nature, Cell, Nature Communications, Cancer Cell, Cancer Discovery, EMBO, Journal of Clinical Investigations, Journal of Clinical Oncology, Leukemia, Journal of Immunology, Cancer and others. He has an h-index of 61.

Dr. Lossos is a recipient of the 2007– Celgene Young Investigator Award for Achievements in Clinical Hematology and the 2012 – Sylvester Comprehensive Cancer Center Outstanding Cancer Research Award. Since 2004 and till 2020 he is recognized as an America' Top Doctor by the A Castle Connolly Guide and in 2011–2016 was recognized as Top Doctor by US News and World Report. He served on an Advisory board of Lymphoma Foundation for more than 10 years and is currently a member of Blood Editorial Board.

## Fabio Efficace, MD

---

*Fondazione GIMEMA – Franco Mandelli Onlus, Roma, Italy*

### CURRENT POSITION

He is the Head of the Health Outcomes Research Unit of the GIMEMA “Gruppo Italiano Malattie EMatologiche dell’Adulto” (GIMEMA) Central Office, Rome (Italy), as well the Chair of the GIMEMA Working Party on Quality of Life.



### AREAS OF EXPERTISE & RESEARCH ACTIVITY

He has been the Principal Investigator of several large-scale international projects on patient-centered outcomes, quality of life, symptoms management as well as digital health technologies in oncology. He has also contributed to the development of international guidelines to raise standards of patient-reported outcomes assessment in clinical trials.

### RESEARCH GRANTS

His research activity has been funded by several academic institutions, federal agencies, patient associations as well as by major pharmaceutical Industries. These include research grants by the US National Cancer Institute (NCI), the European Organisation for Research and Treatment of Cancer (EORTC) and the European Commission (EU).

### AWARDS & HONORS

He has been awarded several international prizes in the area of health outcomes research in oncology. He has served on the Board of Directors of the International Society for Quality-of-Life Research (ISOQOL), the Executive Committee of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Group, and he was also the Chair of the EORTC Quality of Life Group. He was an Adjunct Professor at Feinberg School of Medicine, Department of Medical Social Sciences at Northwestern University, Chicago (IL), USA.

### INVITED INTERNATIONAL LECTURES

He has given several Invited and Keynote Lectures in top academic institutions,

scientific societies and in patient advocates group Meetings both in Europe and in the USA. These include, the Memorial Sloan– Kettering Cancer Center (MSKCC), NYC (USA) the American Society of Hematology (ASH), the European Hematology Association (EHA), the European School of Hematology (ESH), as well as the Chronic Myeloid Leukemia (CML) Advocates Network.

#### EDITORIAL ACTIVITY

He is on the Editorial Board of the Journal of the National Cancer Institute (JNCI), and has served on the Editorial Board of key scientific Journals including: Blood, BMC Cancer and Health and Quality of Life Outcomes (HQLO).

#### ADVISORY BOARD & INTERNATIONAL GRANT REVIEW COMMITTEE

Extensive experience in serving on a number of International Grant Review Committees for research proposals, including the European Commission (EU), for which he has been working as Expert Evaluator, and other several National-based cancer Institutions. He has also been part of key Advisory Committees for important institutions, including Regulatory Agencies (e.g., the US FDA).

#### SCIENTIFIC PRODUCTION & PUBLICATIONS

More than 600 publications, including full papers, book chapters and conference abstracts (H-Inedx: 57). Book chapters have been published by top publishing houses including: Oxford University Press (OUP), American Psychiatric Association (APA) and Enciclopeida Treccani. He has an extensive track record of publications in PubMed (over 285), including ones in top ranking journals, such as the Journal of Clinical Oncology, Lancet Oncology, Lancet Hematology, Blood and Nature Medicine.



## Philipp Le Coutre, MD

---

*Charité – Universitätsmedizin Berlin, Germany*



Philipp le Coutre obtained his medical degree in 1994 at Ludwig-Maximilians-University in Munich, Germany, where he also started his clinical training. As a postgraduate student he worked at The Scripps Institute, La Jolla, San Diego, CA in 1994. In 1996 he commenced a three year postdoctoral period at the National Cancer Institute in Milano, Italy, where his research activities were primarily centered on the role of oncogenic fusion proteins, especially BCR::ABL1, in human leukemias. Here, he contributed pivotal data on the in-vivo efficacy of imatinib and on mechanisms of in-vitro resistance to this drug. Since 1999 he is working at Charité, Humboldt-University in Berlin, Germany. His clinical activities include therapy of acute and chronic myeloid leukemias, chronic myeloid neoplasias and lymphomas. Consequently, he co-authored more than 170 articles on the biology, diagnosis and treatment of human leukemias. Philipp le Coutre is board certified in internal medicine as well as in hematology and oncology. He was appointed Professor of Medicine in 2015 and is currently the deputy director of the Department of hematology and oncology at Campus Mitte, Charité.

He is a member of the American Association of Hematology (ASH) as well as the German Association of Hematology and Oncology (DGHO).

## **Lucia Masarova, MD**

---

*University of Texas MD Anderson Cancer Center, Houston, USA*



Dr. Masarova is an Assistant Professor at the MD Anderson Cancer Center in Houston, Texas at the Department of Leukemia with special interest in myeloid malignancies and myeloproliferative neoplasms. Dr. Masarova's broad clinical knowledge in oncology and malignant hematology has been obtained through trainings in Europe and in the USA, where she trained under the mentorship of the leaders in the field. Current research is dominated by myeloproliferative neoplasms. She has published numerous first-authored articles of original research and is principal investigator of clinical trials for myeloproliferative neoplasms.

## Jason Gotlib, MD

---

*Hematology, Stanford Cancer Center Palo Alto, Palo Alto California*



Dr. Jason Gotlib is Professor of Medicine in the Division of Hematology at the Stanford Stanford Cancer Institute. Dr. Gotlib's research focus is clinical and translational evaluation of novel therapies for myeloproliferative neoplasms, including JAK inhibitors for myelofibrosis (MF), KIT inhibitors for systemic mastocytosis (SM), and more recently, increasingly targeted therapies including an antibody targeting mutant calreticulin and a V617F-mutant selective JAK inhibitor. He has authored more than 250 research articles and reviews in journals such as Blood, Journal of Clinical Oncology, Nature Medicine, and The New England Journal of Medicine.

Dr. Gotlib is Vice-Chair of the NCCN Guidelines Committee on Myeloproliferative Neoplasms. He led clinical development of four FDA-approved drug indications: midostaurin and avapritinib for advanced SM, avapritinib for indolent SM, and pemigatinib for leukemias with an FGFR1 gene rearrangement. Dr. Gotlib currently serves as an Associate Editor for Blood.

## Guillermo Garcia-Manero, MD

*University of Texas MD Anderson Cancer Center, Houston, USA*



Dr. Guillermo Garcia-Manero is the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research in the Department of Leukemia at the University of Texas MD Anderson Cancer Center. He also serves as the Chief of the Section of Myelodysplastic Syndromes and Vice Chairman of the Department of Leukemia at UT MD Anderson Cancer Center. He also serves as Leader of the MDS/AML Moon Shot Program and Program Director of the Leukemia Fellowship Program at MD Anderson Cancer Center. He is the past president of SOHO.

Dr. Garcia-Manero was born in Spain and received his medical degree and training at the University of Zaragoza in Spain and at the Royal Free Hospital in London, UK. From 1993– 1996, he performed his internship and residency in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia, PA. He then continued his training with a fellowship in Hematology and Medical Oncology at the Cardeza Foundation for Hematology Research, Sidney Kimmel Cancer Center, also at Thomas Jefferson University Hospital, where he served as Chief Fellow. In 1999, he became Assistant Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center where he has remained for the rest of his academic career.

Dr. Garcia-Manero's research focuses on understanding the cellular and molecular biology of MDS and AML with an aim to improve therapeutic options for patients with these disorders. His work has been funded by NIH, DoD, LLS, CPRIT, EP Evans Foundation, and the MDS/AML Moon Shot. He has co-authored over 1000 manuscripts. His H-index is 160 and his i10-Index is 1,101 with over 121,000 citations to his work. Currently, he is PI or Co-PI on over 30 active clinical trials focusing on AML and MDS. He directs what is likely the largest single institution unit for patients with MDS in the world, with over 400 patients referred annually, and maintains one of the busiest clinics at MD Anderson. The Section of MDS is comprised of leukemia faculty dedicated to care for patients with MDS and two research laboratories directed by Dr. Colla and Dr.

Wei. In addition, the Section coordinates the work of over 15 research nurses. Dr. Garcia-Manero has received a number of significant awards, such as The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research, the Emil J. Freireich Award for Excellence in Translational Research at MD Anderson, the Giant of Cancer Care in Leukemia, the AAMDSIF Leadership in Science Award, the Ciril Rozman Lecture at the 2024 Annual Meeting of the Spanish Society of Hematology and most recently was inducted as a member of the Association of American Physicians. He has also been recognized as one of the Best Doctors in America each year since 2007. He has trained over 100 fellows and post-doctoral fellows and has been a speaker at multiple national and international forums.

## David A. Sallman, MD

---

*Moffitt Cancer Center, Tampa, Florida, USA*

Associate Member Department of Malignant Hematology  
Moffitt Cancer Center



David Sallman, MD, currently at the H. Lee Moffitt Cancer Center & Research Institute and the University of South Florida, has clinical interests in MDS, AML, and myeloproliferative neoplasms. His research interests focus on the development of novel targeted therapeutic strategies for patients with MDS and AML. Specifically, he studies the genetic drivers of myeloid diseases to improve prognostication for patients and to allow for more personalized treatment. He has published significantly on this topic, including recently in leading journals such as *Leukemia*, *Blood*, and *Journal of Clinical Oncology* and these works are the foundation of clinical trials/translational studies designed to improve the QOL and survival of patients with MDS and AML. He is the PI for multiple ongoing studies focused on higher-risk MDS; has authored or coauthored numerous articles, books, book chapters, and abstracts; and serves as reviewer for multiple journals.

## Eric Padron, MD, PhD

---

Dr. Eric Padron, MD, PhD is a Senior Member and Scientific Director in the Malignant Hematology Department at the H. Lee Moffitt Cancer Center with a research focus in chronic myelomonocytic leukemia (CMML), clonal hematopoiesis, and chronic myeloid neoplasms.



His translational laboratory seeks to identify and implement novel discoveries directly to the clinic. Although mechanistic studies to understand the molecular underpinnings of chronic myelomonocytic leukemia CMML constitute a large portion of his laboratory's efforts, his laboratory singularly views these insights as tools for translation to the clinic to improve the management of patients with Chronic myeloid neoplasms. This urgency is born out of Dr. Padron's CMML clinic in which most of his patients succumb to their disease.

He has been awarded several grants for his genomic studies in the MDS and CMML fields, including the American Society of Hematology Scholar Award, the Evans MDS Foundation Fellow Award, the NCI to study the therapeutic candidacy of long noncoding RNAs, and a large MDS Foundation grant to study molecular aspects of CMML in 1000 patients.

Dr. Padron has successfully translated his lab discoveries into several trials in the CMML clinic. This is exemplified by his bench-to-bedside efforts that have led to the successful completion of a phase 1 and 2 trial testing ruxolitinib in CMML. Dr. Padron has published over 215 peer-reviewed manuscripts in the area of myeloid malignancies. Importantly, Dr Padron was awarded an R37 NCI grant to develop a CMML PDX model that can recapitulate the human condition. In this context, the Padron lab has generated over 2000 CMML PDX from over 100 unique patients.

## Valeria Santini, MD

---

*University of Florence, Florence, Italy*



Valeria Santini is Associate Professor of Hematology at the University of Florence, Italy. She runs the MDS Unit– Hematology– Department of Experimental and Clinical Medicine– AOU Careggi, University of Florence. Her interests are focused on clinical and translational research in MDS and elderly AML. Professor Santini is President of the Scientific Committee of Fondazione Italiana per lo studio delle sindromi mielodisplastiche (FISiM) and Italian Network of MDS Registries, Vice President of the Italian Society of Hematology (SIE). She belongs to ASH, EHA SOHO, and MDS Foundation. Member of the medical scientific board of AA&MDS International Foundation. She is also an author of more than 200 peer-reviewed papers published in international journals, she is member of the Editorial board of Blood Neoplasia and Leukemia Journal and has been member of the Editorial board of Blood journal, and documented reviewer for high impact factor scientific journals. She has been an invited speaker at numerous international meetings including the American Society of Clinical Oncology (ASCO 2007: educational session on MDS, ASCO 2024 and 2025 educational session), American Society of Hematology (ASH 2012, ASH 2016: educational sessions on MDS, ASH 2023 Educational Spotlights), European Haematology Association (EHA 2016, 2020, 2022, 2025: Educational sessions on MDS) and national haematology societies of several countries.



## **Delphine Rea, MD**

---

*Hopital Saint-Louis, Paris, France*

Dr Delphine Rea is appointed at Saint-Louis University Hospital, Paris, France, where she works as a physician in the Department of Hematology.



Her main clinical and research interest focuses on malignant myeloid disorders. She is responsible for the Chronic Myeloid Leukemia clinical care and research program. She has been the principal investigator or investigator of many academic- or industry-sponsored clinical trials dedicated to CML, including pivotal studies that have led to the approval of tyrosine kinase inhibitors or treatment-free remission studies.

She belongs to the board of directors of the French cooperative group of CML (Fi-LMC), contributes to the CML project of the European LeukemiaNet, to the organization committee of European School of Haematology (ESH) iCMLf annual conference, to the Society of Hematologic Oncology (SOHO) annual meeting education committee and to the scientific advisory board of iCMLf.

## **Simona Soverini, PhD**

---

*Alma Mater Studiorum Universita di Bologna, Italy*

Simona Soverini is Associate Professor of Hematology at the Department of Medical and Surgical Sciences of the University of Bologna and head of the Myeloid Leukemia Research group at the Institute of Hematology “Lorenzo e Ariosto Seragnoli” at the S. Orsola University Hospital in Bologna, Italy. She obtained her MSc in Molecular Biology and her PhD in Clinical and Experimental Haematology from the University of Bologna.



Her research focuses on chronic myeloid leukemia and systemic mastocytosis. Professor Soverini is author of over 180 publications in peer-reviewed journals, with a h-index of 53.

She is a reviewer for a number of international journals, including Blood, Leukemia, Haematologica, Clinical Cancer Research and British Journal of Haematology, and sits in the Editorial Boards of Journal of Hematology & Oncology, Frontiers in Oncology and International Journal of Molecular Sciences.

She is a member of the board of Directors of the Italian Society of Experimental Hematology (SIES) and a member of the European Hematology Association (EHA), the American Society of Hematology (ASH) and the Society of Hematological Oncology (SOHO). She has served on the Scientific Program Committees for EHA and SOHO congresses.

## Giuseppe Saglio, MD

---

*University of Turin, Italy*

Giuseppe Saglio is Emeritus Professor of Haematology and Internal Medicine at the University of Turin. Professor Saglio has been coordinator of the PhD programme in Medicine and Experimental Therapy of the University of Turin and Director of the Department of Clinical and Biological Sciences of the same University.



He has published more than 600 peer-reviewed articles in the fields of molecular pathogenesis of haematological diseases, molecularly targeted therapy and molecular characterization of haematological malignancies.

In 2017 Prof Saglio was nominated Knight of the Italian Republic for scientific merits and for his long lasting service for the Italian University.

## Nirav N. Shah, MD

---

Medical College of Wisconsin, Milwaukee, Wisconsin, USA


Nirav Shah, MD, MSHP, is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in lymphoma, CAR-T cell therapy, and stem cell transplant at Froedtert Hospital. He graduated with honors and Alpha Omega Alpha Honor Society membership from the University of Illinois at Chicago College of Medicine in 2008. He then completed his Internal Medicine residency at Massachusetts General Hospital in Boston, Massachusetts in 2011. Post-residency, he took a position at Northwestern Memorial Hospital in Hospitalist medicine before proceeding to the University of Pennsylvania where he completed both hematology/oncology fellowship and a Master's degree in Health Policy research in 2015. His research focus is in the area of novel agents and cell therapy development for hematological malignancies. He is currently Director of the Bone Marrow Transplant and Cellular Therapy Program at the Medical College of Wisconsin.



## Issa Khouri, MD

---

*University of Texas MD Anderson Cancer Center, Houston, USA*



Issa Khouri, MD, is professor of medicine in the Department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas. He earned his medical degree from the University of Rome, “La Sapienza” Medical School. He completed a transitional residency, an internal medicine residency, and a chief residency in internal medicine at the Northeastern Ohio University College of Medicine, followed by a fellowship at MDACC.

Dr Khouri’s area of scholarly activity is blood and marrow transplantation for lymphoid malignancies an area where he gained international reputation. His seminal work in this field has helped define the role of autologous and allogeneic transplantation for these diseases. He also developed an effective program for novel, less toxic non-myeloablative allogeneic transplantation that resulted in the most important paradigm shift in transplantation in this field. He has developed a special interest in strategies for preventing or treating relapse by enhancing immune system activity, focusing on the role of monoclonal antibodies, lenalidomide, ibrutinib and, more recently, checkpoint inhibitors.


Dr Khouri is a member of several national and international societies, including the Mantle Cell Consortium, the International Bone Marrow Transplant Registry, and the Autologous Bone Marrow Transplant Registry. He has received several awards, including the MD Anderson/Division of Cancer Medicine Award for Excellence in Team Science – CLL. His work has been widely recognized, and he has authored several practice-changing scientific publications in the fields of lymphoma, leukemia, and transplantation.

## Koen Van Besien, MD, PhD

---

*UH Seidman Cancer Center, Cleveland, Ohio, USA*

Dr. van Besien is the current Chief of the Division of Hematology Cell Therapy, the Director of the Wesley Center for Immunotherapy at Seidman Cancer Center and Professor at Case Western Reserve University. Previously he was Director of the Cell Therapy and Transplant Programs at University of Chicago and at NYP/Weill Cornell. Dr. van Besien is a hematologist and oncologist and clinical researcher with over 30 years of experience in stem cell transplant and cellular therapy research with a focus on transplant for lymphoid disorders and more recently on alternative donor transplantation. As Director of the Wesley Center for Immunotherapy, Dr. van Besien oversees a large translational research operation with capacity to produce genetically modified cell products for clinical investigational use. Dr. van Besien has a long history of mentoring and many of his trainees have gone on to successful academic careers.



## **Robin Foà, MD**

---

*Department of Translational and Precision Medicine,  
Sapienza, University of Rome, Rome, Italy*



Medical degree, Turin.

1976–1979 MRC Leukaemia Unit, Hammersmith Hospital, London.

1980–1999 Associate Professor, University of Turin.

1991–1992 Sabbatical, Memorial Sloan–Kettering Cancer Center, New York.

1999–2019 Professor of Hematology, Sapienza University of Rome.

2003–2019 Head of Hematology, Sapienza University of Rome.

2019\* Emeritus Professor of Hematology, Sapienza University of Rome.

2007–2013. President–Elect, President and Past–President of EHA.

Chairman Education Committee and Outreach Unit of EHA up to June 2017.

Member EHA's Global Outreach Committee up to June 2023.


Has been chairman of the GIMEMA Working Party for chronic lymphoproliferative disorders, and member of the Working Party for acute leukemias. Has authored over 880 indexed papers. Has been co-editor of *Leukemia and Lymphoma*, and associate editor of the *British Journal of Hematology* and of *The Hematology Journal*, editor-in-chief of *The Hematology Journal* and of *Haematologica*.

He received the EHA Education & Mentoring Award at the 23rd EHA Congress (Stockholm 2018) and the EHA José Carreras Award at the EHA 26th Congress (Frankfurt 2023).

## Nicolas J. Short, MD

---

*University of Texas MD Anderson Cancer Center, Houston, Texas, US*



Dr. Nicholas Short is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Short is a clinical and translational investigator in adult leukemias, with a particular emphasis on measurable residual disease and the development of phase I and II clinical trials of novel agents and combinations for patients with acute leukemias. Dr. Short has authored over 200 peer-reviewed manuscripts and numerous abstracts that have been presented at national and international conferences, including the American Society of Hematology and the American Society of Clinical Oncology. For his accomplishments in the field of leukemia research he has received a number of awards, including the American Society of Clinical Oncology Young Investigator Award and the American Society of Hematology Junior Faculty Scholar Award in Clinical Research.



## **Martin Dreyling, MD**

---

*LMU Hospital, Munich, Germany*

Martin Dreyling is Professor of Medicine and head of the lymphoma programme in the Department of Medicine III, LMU Hospital, Munich.



His scientific focus is on the molecular basis of malignant transformation, and is especially interested in innovative therapeutic approaches, like inhibitors of the B-cell receptor pathway and immunological approaches.

Prof. Dreyling is coordinator of the European MCL Network and past president of the German Lymphoma Alliance as well as EHA executive board member.

## DIAMOND



## PLATINUM

Johnson & Johnson

abbvie

AstraZeneca 

## GOLD

 Bristol Myers Squibb®



 GILEAD

sanofi

MEDISON 

*Lilly*

 NEOPHARM ISRAEL  
NEOPHARM GROUP

 astellas